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Glycine N-Methyltransferases: A Comparison of the Crystal
Structures and Kinetic Properties of Recombinant Human,
Mouse and Rat Enzymes
Svetlana Pakhomova,1 Zigmund Luka,2 Steffi Grohmann,1 Conrad Wagner,2* and Marcia E. Newcomer1
1Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana
2Vanderbilt University School of Medicine, Department of Biochemistry, Nashville, Tennessee
ABSTRACT Glycine N-methyltransferases (GN-
MTs) from three mammalian sources were com-
pared with respect to their crystal structures and
kinetic parameters. The crystal structure for the rat
enzyme was published previously. Human and
mouse GNMT were expressed in Escherichia coli in
order to determine their crystal structures. Mouse
GNMT was crystallized in two crystal forms, a mono-
clinic form and a tetragonal form. Comparison of
the three structures reveals subtle differences,
which may relate to the different kinetic properties
of the enzymes.
The flexible character of several loops surround-
ing the active site, along with an analysis of the
active site boundaries, indicates that the observed
conformations of human and mouse GNMTs are
more open than that of the rat enzyme. There is an
increase in kcat when going from rat to mouse to
human, suggesting a correlation with the increased
flexibility of some structural elements of the respec-
tive enzymes. Proteins 2004;57:331–337.
© 2004 Wiley-Liss, Inc.
Key words: glycine N-methyltransferase; X-ray crys-
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INTRODUCTION
The enzyme glycine N-methyltransferase (GNMT) is
abundant in mammalian liver, comprising between 0.5
and 3% of the cytosolic protein,1–3 depending on the
species. Its relative abundance may indicate an important
physiological role for its activity. GNMT catalyzes the
transfer of a methyl group from S-adenosylmethionine
(SAM) to glycine to yield S-adenosylhomocysteine (SAH)
and N-methylglycine (sarcosine). The enzyme appears to
play a significant role in maintaining the physiologically
appropriate SAM-to-SAH ratio, which is thought to be a
critical component of the regulation of the methylation
potential of the cell.4 In addition, GNMT is bound to
5-methyl-tetrahydrofolate pentaglutamate in vivo,5 and
the folate coenzyme behaves as an inhibitor of GNMT in
the enzymatic reaction.6 This is part of a regulatory
scheme that ties the de novo synthesis of methyl groups by
the one-carbon folate pool to the availability of pre-formed
methyl groups in methionine.7 GNMT is abundant in the
liver, the pancreas and apparently also in the prostate. It
is also found in cells that carry out secretion.8 The protein
sequence of GNMT from cloned cDNAs of several organ-
isms, including humans, show a high level of sequence
identity (90% of the amino acids are identical in the
human, rat and mouse forms).3 All GNMTs that have been
purified are tetramers consisting of four identical mono-
mers, each having a Mr of 32.5 kDa. All GNMTs bear an
N-terminal acetyl group on the initial valine,3 and it has
been shown that in the rat liver enzyme the enzyme is
phosphorylated.9
Detailed structural and kinetic studies of the rat recom-
binant form of the enzyme have been reported, and a
mechanism for the enzymatic reaction has been proposed
based on crystal structures of rat GNMT.10–13 According
to the proposed mechanism, significant conformational
changes occur during the methyltransferase reaction. As
defined by Fu et al.,10 the rat GNMT monomer is com-
poised of three domains: the N-terminal domain (residues
1–36), the C-terminal domain (residues 37–175 and 243–
292) and the S-domain (residues 176–242). Three basic
conformational states of rat GNMT, an ‘inactive’ or ‘closed’
structure, an ‘open’ structure and an ‘active’ structure
have been described.10–13
In the ‘closed’ conformation (observed in the GNMT-SAM-
acetate structure10 and the apo-form11), the active sites of
GNMT in each monomer are covered by the N-terminal
domain from the adjacent subunit. No apparent entrance
to or exit from the active site is observed. This conforma-
tional state was proposed to be the ‘initial stage’ of the
methyltransferase reaction.
In the ‘open’ conformation (R175K GNMT-SAH struc-
ture12), the entire N-terminal domain is highly disordered,
and the S-domain is significantly shifted relative to its
orientation in the closed conformation. It has been sug-
gested that the N-terminal domain must move out from
the active site of the adjacent subunit into the solvent
region in order to provide an entrance for SAM and glycine
into the active site.12 The SAH binding site in this
structure corresponds to the SAM binding site in other
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methyltransferases. This conformational state has been
linked to the product release stage in the latest work by
the same authors.13
In the ‘active’ conformation (R175K GNMT-SAM struc-
ture13), described as near the transition state or active
conformation, the N-terminus is directed into the solvent.
However, in contrast to what is described as the ‘open’
form of the enzyme, only residues 1–18 of the N-terminus
are highly disordered. In addition, residues 126-127 and
226–234 are slightly disordered. In this structure, the
SAM binding site is consistent with the SAM binding site
in other methyltransferases.
In order to determine whether the proposed mechanism
for the rat enzyme is consistent with the structures and
kinetic parameters of other mammalian GNMT enzymes,
crystallographic and kinetic studies were undertaken with
human and mouse forms of the enzyme.
A comparison of the properties of GNMTs from human,
rat, rabbit and pig livers was carried out by Ogawa and
coworkers.14 The enzymes were only partially purified.
Nevertheless, the values for the substrate concentrations
at which half maximal activity ([S]0.5) for SAM and glycine
was reached of the enzyme from the rat were much lower
(by 18 to 5%) than the corresponding values from the
human enzyme. The [S]0.5 values for SAM and glycine for
the rat enzyme were also much lower than the correspond-
ing values for the rabbit and pig enzymes.
The identification of naturally occurring mutations in
the enzyme necessitated a structural determination of the
human form of GNMT. We discovered two sets of patients
with mutations in the coding region of the gene for GNMT.
In one family, both brother and sister were found to be
compound heterozygotes with an L49P mutation on one
allele and H176N on the other.15,16 The other patient had
an N140S mutation.17 In each case, when the L49P and
the H176N mutations were expressed in E. coli, the
recombinant enzyme displayed greatly reduced activity.18
When the N140S mutation was expressed in E. coli, it had
almost no activity. Although the structure of the rat
enzyme can help to interpret the consequences of these
mutations, a model for the human enzyme would reveal
any unforeseen structural differences between the native
rat and human enzymes. We report here the structures of
the human and mouse enzymes and provide a structural




GNMT cDNAs were cloned and expressed in the pET-
17b expression vector, as reported earlier.19 Briefly, the
GNMT cDNAs were cloned from the mouse and human
poly-A RNA and from the rat Marathon-Ready RNA
(Clontech, Palo Alto, CA). Cloned cDNAs were introduced
into pET-17b expression vector. Expression was completed
according to the standard approach for that expression
system at 20°C for 17-18 h with 1 mM IPTG.
GNMT was isolated and purified by ammonium sulfate
precipitation of the enzyme from crude extract, followed by
ion-exchange chromatography on a DE-52 column, as
described previously.19 Further purification was per-
formed with a Sephacryl S-200 size-exclusion column. The
final purity of all GNMT samples was at least 95–97%.
Protein Crystallization
Human GNMT
Crystals of human GNMT were grown at 4°C by the
hanging drop vapor diffusion method after mixing 1 L of
the enzyme at 8.4 mg/mL in 50 mM Tris-HCl pH 8.0, 200
mM NaCl, 14 mM -mercaptoethanol, 1 mM EDTA with 1
L of the reservoir solution [9–11% (w/v) polyethylene
glycol 4000, 0.1M Na-citrate pH 5.6-6.0]. Crystals usually
appeared overnight and grew to full size within 1-2 days.
Mouse GNMT
Crystals of mouse GNMT were grown at 22°C by the
hanging drop vapor diffusion method by mixing equal
volumes of enzyme at 5.7 mg/mL in 20 mM Tris-HCl pH
7.5, 90 mM NaCl, 14 mM -mercaptoethanol, 1 mM EDTA
and the reservoir solution [15% (w/v) polyethylene glycol
4000, 0.1M Tris-HCl pH 8.5 and 5% isopropanol]. Crystals
of both forms (P21 and P41212) grew under the same
conditions and often in the same drop.
Data Collection
Prior to data collection, a suitable crystal was dipped for
30 s in a modified mother solution with the addition of 20%
ethylene glycol as a cryo-protectant. All diffraction data
were collected at 100K with a cryo-stream cooler from
Oxford Cryojet with a 345 mm MAR Research imaging
plate detector mounted on a NONIUS FR591 rotating
anode generator (CuK radiation). Data were processed
with DENZO20 or Mosflm21 and scaled using Scalepack20
or Scala.22 Data collection and data processing statistics
are given in Table I.
Crystal Structure Determination
All crystal structures were solved by the molecular
replacement (MR) procedure implemented in the CNS
package.23 A dimer of the rat GNMT structure [Protein
Data Bank (PDB) accession code 1XVA] was used as a
search model for human GNMT and the tetragonal form of
mouse GNMT; the structure of the monoclinic form of
mouse GNMT was solved using a dimer from the tetrago-
nal form of the same protein. The positioned MR models
were refined using the maximum likelihood refinement in
REFMAC.22 Twofold non-crystallographic symmetry re-
straints and bulk solvent corrections were applied in every
case. The program O24 was used to build the initial models
and throughout the refinement. Refinement statistics are
listed in Table I. Details of refinement of each of the
structures follow.
Human GNMT
No significant electron density was observed for residues
1–4, 126–128, 225–235 of monomer A or 1–4, 226–235 of
monomer B, an indication that these regions are highly
mobile or disordered. An electron density in the Fo–Fc
map, which can be attributed to a citrate molecule, was
found in the active site. Additional electron densities on
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cysteines 187 (monomer A) and 187, 264 and 284 (mono-
mer B) were interpreted as coming from covalently-bound
-mercaptoethanol (BME) molecules, as the protein buffer
contained BME.
Tetragonal Form of Mouse GNMT
The final model consisted of residues 1–224 and 234–
292 for monomer A and 1–225 and 234–292 for monomer
B. No electron density was observed for residues A225–
A233 or B226–B233. A difference Fourier map suggests
the presence of a Tris molecule in the active site of the
protein. Covalently bound BME was modeled at cysteines
A146, A246, B146 and B262.
Monoclinic Form of Mouse GNMT
In this crystal form, an asymmetric unit is composed of
two tetramers. There is no electron density for residues
A224–A234, B225–B234, C228–C234, D226–D231, E228–
E233, F225–F233, G225–G233 and H225–H234 (A–H
refer to different monomers). The active site does not have
any ‘extra’ electron density such as that attributed to a
Tris molecule in the tetragonal form. Covalently-bound
BME residues were found for cysteines A262, A282, B57,
D185, D246, D262, E246, F282, G246 and G282.
The refined coordinates have been deposited in the PDB
with the following accession codes: human GNMT, 1R74;
tetragonal form of mouse GNMT, 1R8X; monoclinic form of
mouse GNMT, 1R8Y.
GNMT Activity
GNMT activity was assayed using the charcoal adsorp-
tion method, as described earlier.25 A 100 L reaction
mixture contained 200 mM Tris-HCl buffer pH 7.5, 5 mM
dithiotreitol (DTT), about 2 g enzyme and both sub-
strates, SAM and glycine, at the appropriate concentra-
tions. Each incubation also contained [3H-CH3]-SAM (3–
5  103 dpm). After incubation at 25°C for 15 min, the
reaction was stopped by the addition of 50 L 10%
trichloroacetic acid. A 250 L suspension of acid-treated
charcoal in 0.1M acetic acid was added, and the suspension






Wavelength 1.5418 1.5418 1.5418
Resolution (Å) 2.55 2.95 3.05
Space group P21212 P41212 P21
Cell dimensions
a (Å) 75.84 70.70 107.98
b (Å) 83.23 70.70 108.30
c (Å) 114.88 266.03 119.01
 (°) 90.00 90.00 90.00
 (°) 90.00 90.00 93.66
 (°) 90.00 90.00 90.00
Number of monomers per asymmetric unit 2 2 8
Number of unique reflections 23864 14973 51310
Rsym
ab (%) 5.1 (38.9) 6.8 (43.1) 6.6 (40.3)
Completeness (%) 98.3 (98.3) 99.7 (99.7) 99.2 (100)
Redundancies 3.7 3.7 3.6
I/(I) 9.9 (1.8) 6.7 (1.8) 19.6 (3.1)
Refinement Statistics
Resolution range 12-2.55 10.5-2.95 13-3.05
Number of reflections used in refinement 19506 13784 46863
 Cutoff used in refinement none none none
R/Rfree
c (%) 22.18/26.61 20.68/27.27 22.22/28.51
Number of refined atoms
Protein 4230 4356 17552
Heterogen atoms 42 32 40
Water 60 21 14
Average B-factors (Å2) 33.7 27.2 24.7
RMS deviations
Bonds (Å) 0.027 0.024 0.017
Angles (Å) 2.167 2.167 1.650
Ramachandran statistics
Most favored regions (%) 88.6 83.9 86.1
Disallowed regions (%) 0.0 0.0 0.0
aValues in parentheses are for the highest-resolution shell.
bRsym  	Ii 
 I / 	Ii, where Ii is the intensity of the in observation and I is the mean intensity of
the reflection
cR  	Fo  
  Fc/	Fo, where Fo and Fc are the observed and calculated structure factor amplitudes. Rfree
is calculated using 6.9%, 5.6% and 3.0% of reflections omitted from the refinement for the human GNMT,
tetragonal form and monoclinic form of mouse GNMT respectively.
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was incubated on ice for 15 min. After centrifugation in a
microcentrifuge, the radioactivity in the supernatant was
counted with a Tri-Carb Liquid Scintillation Analyzer
(Packard Instrument Co., Meriden, CT). Km values for
SAM and glycine were obtained by varying the concentra-
tion of one substrate in the presence of saturating concen-
trations of the other.
Quaternary Structure
The quaternary structures of the expressed proteins
were determined by size-exclusion chromatography on the
ÄKTA Purifier System (Amersham Pharmacia, Piscat-
away, NJ). Chromatography of the native proteins was
performed on a Superose-12 column in a buffer composed
of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 14 mM BME at
flow rate of 0.5 mL/min at 22°C. The sample volume was
100 L, and the column was calibrated with chymotrypsin,
ovalbumin, bovine serum albumin and aldolase.
Protein Assay
The concentrations of protein samples were determined
by the BCA method using bovine serum albumin as a
standard.26 Protein purity was determined by SDS–PAGE
electrophoresis and by N-terminal Edman sequencing.
Gels were documented using a NucleoVision 760 Imaging
Workstation (NucleoTech, San Mateo, CA).
RESULTS AND DISCUSSION
The primary goal of our work was to study how differ-
ences in the amino acid sequences of three glycine N-
methyltransferases could affect the catalytic properties of
these enzymes. The amino acid sequences of rat, mouse
and human GNMTs show approximately 90% sequence
identity (Fig. 1). The rat and mouse proteins consist of 292
amino acid residues, while the human GNMT consists of
294 residues due to an insertion at position 126. Among
these three GNMTs, there are 31 differences in the amino
acid residues. Most of these are conservative substitutions,
but there are also substitutions that could potentially
change the local conformation of the proteins, such as a K
to H and A to S in the region 113–119, or the D to G
substitution at the C-terminus. The crystal structure of rat
GNMT indicates that the differences in amino acid se-
quences are located on the surface of the protein molecule,
far from the active site. Hence, they should not directly
affect the catalysis. However, differences in amino acid
composition result in differences in general protein charac-
teristics. For instance, the predicted value of pI for human
GNMT is 6.6, while for the mouse and rat forms it is 7.1.
Quaternary Structure
Expressed human, rat and mouse GNMTs were tetram-
ers as they were eluted from the Superose-12 column in
one peak with elution volumes of 12.55, 12.73 and 12.90
mL for human, mouse and rat proteins respectively. This
corresponds to an apparent Mr of 130 kDa (data not
shown). While the differences in elution volume of GNMTs
were small, they were reproducible in different buffers.
This could be explained as a result of the smaller Stokes
radii of mouse and rat enzymes compared to human
protein and is a result of a more compact conformation of
rat and mouse GNMTs.
Enzyme Kinetics
The kinetic parameters for human, rat and mouse
GNMTs are presented in Table II. The Km(SAM) values for
the human enzyme are higher than the corresponding
values for mouse and rat. The Km(gly) value of human
GNMT is three times that of the rat enzyme. The human
enzyme has the highest kcat, while the rat has the lowest.










Human* 96.4 281.0 0.34 12.2 7.90
Mouse 43.6 180.3 0.24 3.6 12.11
Rat 33.5 107.0 0.31 2.0 16.75
Data from (ref 18).
Fig. 1. Sequence alignment of mouse (m), rat (r) and human (h) GNMTs.
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This was measured when the enzyme was saturated with
both substrates and is effectively the turnover number.
When the kcat/Km is calculated for the individual sub-
strates, the value for SAM of the human enzyme remains
highest, but the opposite is the case with respect to glycine.
This latter value is an index of the efficiency of the enzyme.
The human enzyme appears to be most efficient with
regard to SAM but not to glycine.
Previous studies comparing GNMT from various species
showed that human GNMT had a higher [S]0.5 for SAM
and glycine than did rat GNMT.3 It should be noted that
these previous studies were done with crude ammonium
sulfate fractions from liver, and the results reported here
are for the purified recombinant enzymes expressed in E.
coli. Moreover, rat liver GNMT is phosphorylated, while
the recombinant enzymes expressed in E. coli probably are
not.27 It is not known what effect this post-translational
modification has on the kinetics of GNMT. Therefore it is
probably not informative to try to compare the relative
activities from different species when there is such a
difference in the protein preparations. In the case of rat
GNMT, we have measured the [S]0.5 for SAM and glycine
in both purified liver28 and recombinant enzymes (Table
II). For rat liver, the [S]0.5 for SAM and glycine were 0.39
mM and 0.91 mM, respectively. For the rat recombinant
enzyme, the corresponding values were 0.22 mM and 12.2
mM, respectively. We suggest that the post-translational
modification affects the affinities of the substrates.
Conformations of Human and Mouse GNMTs
The crystal structure analyses of human GNMT and two
crystal forms of mouse GNMT, as expected, revealed very
similar molecular conformations as well as the typical
conformation for rat GNMT tetrameric assembly [Fig.
2(a)]. The highest root mean square (RMS) deviation of
0.727 Å (calculated over 274 equivalent CA atoms) was
observed between the monomers of the human and rat
enzymes. The overall molecular conformation is basically
the previously described ‘closed’ form of rat GNMT. How-
ever, significant conformational differences were observed
in the 225–233 loops (the region that, in the rat enzyme, is
disordered in the ‘open’ and ‘active’ forms of the enzyme).
In the human GNMT structure, as well as in the struc-
tures of the mouse enzyme, loops 225–235 are highly
disordered. These new structures display features of the
‘inactive’ and ‘active’ forms of the rat enzyme. Loops
127–134, which contain the two amino acid insertion in
human GNMT, are also disordered, just as in the ‘active’
form of rat GNMT. In contrast, this loop is ordered in both
Fig. 2. (a) A ribbon representation (stereo) of the human GNMT
tetramer. Protein monomers are shown in different colors; the active
site-bound citrate molecules are included as space-filled renderings. (b)
Structure of a monomer of human GNMT with bound citrate molecule in
the active site. Significantly disordered parts of the monomer: a flexible
loop 225–236 (magenta) and a helical region 22–41 (red) are shown.
Fig. 4. Flexible elements in GNMT structures. (a) Superimposition of residues 28–48 and 189–205 from
eight independent monomers in monoclinic form of mouse GNMT. (b) Superimposition of the same parts in rat
(shown in green), mouse (red) and human (green) GNMT. (c) Representative portion of the final 2Fo–Fc map
calculated around the ‘missing’ loop 225–236 in the structure of human GNMT contoured at 1. Superimposed
equivalent loops from inactive (orange), open (green) and active (magenta) forms of rat GNMT are shown.
GLYCINE N-METHYLTRANSFERASES 335
forms of mouse GNMT, and so in this area the mouse
enzyme resembles the inactive conformation of rat GNMT.
Another significantly flexible part of the human GNMT
molecule includes N-terminal domain residues 21–41, the
region that ‘corks’ the active site in the closed form of rat
GNMT [Fig. 2(b)]. In addition, residues 1–4 are not visible
on electron density maps. The breakage of the antiparallel
-sheet hydrogen bonds between the tail sections of the
N-termini (residues 2–7) of adjacent subunits is proposed
to be the first of a series of conformational changes that
must occur in the catalytic cycle of the rat enzyme.12 In
this model, SAM competes with the U loop (residues 9–20)
for the active site. Depending on the concentration of SAM,
the active open (high SAM concentration) or the inactive
closed (low SAM concentration) conformation is formed. In
the ‘open’ form, residues 21–40 have turned into a solvent
region, and thus glycine can enter the active site through
the channel opened by the movement of helical residues
24–55 (helix a as designated by Fu at al.10). Human
GNMT was crystallized without the addition of SAM, and
thus the SAM binding site was filled by the U loop. The
bound citrate molecule, however, was found in the glycine
binding site in the position of the acetate ion in the active
form of rat GNMT (Fig. 3) with similar hydrogen bonds to
Y33, Y222 (Y220 in rat) and N140 (N138 in rat). Hence, a
disordered helix a could represent a likely entrance for a
substrate into the active site in human GNMT. Superimpo-
sition of molecules of available crystal structures of GN-
MTs has shown that residues 37–42 of helix a are indeed
between the most flexible parts in GNMT molecules [Fig.
4(a)]. They even have different conformations in all eight
independent protein monomers in the monoclinic form of
mouse GNMT [Fig. 4(b)].
It is interesting that Tris molecules bind in a different
place in the tetragonal form of mouse GNMT compared to
the location of citrate binding at the glycine site in human
GNMT (Fig. 3). A comparison to the structure of the active
form of rat GNMT shows that Tris occupies the SAM
binding site. The active site is completely empty in the
monoclinic form of mouse GNMT. Residues 225–236 are
still highly disordered, however, just as they are in the
tetragonal form and the structure of human GNMT.
Of all known methyltransferases, GNMT is unique in
that it has an additional S-domain (residues 176–242).
Hence, it is reasonable to assume that this domain should
be involved in the glycine–N-methyltransferase reaction.
Indeed, the S-domain covers the active site and represents
a very mobile part of the molecule. Residues 188–192 are
flexible in all known GNMT structures except for the
apo-form of rat GNMT. For example, this region of the
polypeptide chain has two conformations in the inactive
form of rat GNMT. In addition, the eight monomers of the
mouse monoclinic structure display different conforma-
tions in this region [Fig. 4(b)]. The ‘apex’ of the S-domain,
the loop composed of residues 220–244, has distinctly
different conformations in the inactive, active and open
forms of rat GNMT [Fig. 4(c)]. This part of the structure is
significantly shifted in the open form compared to the
inactive one. It has a completely different conformation in
the active form of rat GNMT, with residues 226–234 being
significantly disordered (their B-factors are higher than 50
Å2). In the human and mouse GNMT structures, the
electron density is completely missing for those residues,
suggesting that they are highly mobile or disordered [Fig.
4(c)].
All these observations show that, despite the fact that
overall molecular structures of human and mouse GNMTs
resemble the one observed in the inactive form of rat
GNMT, the human and mouse GNMT enzymes are more
flexible than the rat enzyme. The observed high disorder of
loop 225–233 in the human and mouse GNMTs and loop
127–134 in human GNMT makes these regions resemble
the active conformation of rat GNMT. The observed confor-
mational heterogeneity of residues 37–42 and 188–192,
positions close to the active site, in the human and mouse
GNMTs, along with the appearance of buffer molecules in
the active sites of the proteins (binding of a citrate
molecule in the glycine binding site of human GNMT), also
suggests that the observed conformations of human and
mouse GNMTs may be considered to be equivalent to the
intermediate states between the inactive and the active
forms of the rat enzyme.
CONCLUSIONS
The results of crystal structure analysis have shown
that both human GNMT and mouse GNMT in both crystal
forms are more flexible than the rat enzyme. This is in
agreement with the catalytic efficiency of the rat, mouse
and human recombinant glycine N-methyltransferases.
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